Blocking GPR182 to enhance melanoma immunotherapy
Melanoma Immunotherapy with GPR182 blockade
This study is looking at how blocking a specific receptor called GPR182 might help make immunotherapy work better for people with melanoma by allowing more immune cells to attack the tumors, especially those that are currently not responding well to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11005399 on NIH RePORTER |
What this research studies
This research investigates how blocking the GPR182 receptor can improve the effectiveness of immunotherapy for melanoma patients. It focuses on understanding the role of GPR182 in limiting the infiltration of immune cells, specifically CD8+ T cells, into tumors. By studying the interactions between GPR182 and chemokines, the research aims to develop strategies to convert 'cold' tumors, which are less responsive to treatment, into 'hot' tumors that can better respond to immunotherapy. The approach includes both laboratory experiments and potential applications in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with late-stage melanoma who have not benefited from current immunotherapy treatments.
Not a fit: Patients with early-stage melanoma or those who have already responded well to existing immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for melanoma patients who currently do not respond to existing immunotherapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways to enhance anti-tumor immune responses, indicating potential for success in this novel approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Zhu, Yuwen — University of Colorado Denver
- Study coordinator: Zhu, Yuwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.